Health

Health is the most personal and important topic for people, yet there is a range of associated problems, such as disparities in medical access, shortage of doctors, increasing burden on medical workers, and surging medical costs. The Fujifilm Group started producing X-ray film in 1936, soon after the company’s establishment. Since then we have been a long-term contributor in the field of Medical Diagnosis. Our medical business has recently expanded into the Prevention and Treatment fields, as a part of a strategic move towards the group’s growth. We are continuously striving to widen our contribution to promoting people’s health and welfare. In this new CSR Plan, we set out four priority issues based on the scale of our contribution to help solving the social challenges, identified through reviewing all the products, services, and technologies that we possess.

The Fujifilm Group aims to be a total healthcare company and is making steady progress in strengthening its business structure. Particularly in the field of medial systems, our medical IT systems and diagnostic ultrasound systems have a good reputation in the market, with sales expanding across the world.

In 2015, we acquired TeraMedica, Inc. in the U.S. in order to contribute to more efficient medical imaging management and diagnoses. We also made contributions to building network systems that link a local government and related organizations. We also started a new business collaboration in order to establish technology to build a rapid diagnosis system for tuberculosis, one of the world’s three major infectious diseases, based on our own early detection technology for influenza virus.

In the field of regenerative medicine, we expanded our business strengthening the partnership with our group companies, Japan Tissue Engineering Co., Ltd. and Cellular Dynamics International, Inc. which has become a consolidated subsidiary.

Further, in the pharmaceutical field, we expanded the biopharmaceutical contract manufacturing business, and promoted new drug development through starting clinical trials of two anticancer drugs in the U.S.

In the filed of medical systems, we plan to introduce systems that assist efficient management and diagnosis of medical images. Other contributing prospects include promotion of a portable diagnostic ultrasound system that works well in remote locations and emergency situations, and unique endoscopes—such as transnasal endoscopes and models using laser light. We also plan to enhance the lineup of functional products that use our proprietary technologies in the life science field. Our focus in the pharmaceutical business includes further enhancement of biopharmaceutical contract manufacturing and the development of new drugs that meet “unmet medical needs,” such as treatment for Alzheimer’s disease and anticancer drugs. We are also strengthening our regenerative medicine business through acceleration of products and industry-government-academia collaboration, aiming to further contribution to the industry.